Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
Open Access
- 1 February 2009
- journal article
- Published by Informa UK Limited in Pharmacogenomics and Personalized Medicine
- Vol. 2, 1-8
- https://doi.org/10.2147/pgpm.s4608
Abstract
Peer reviewed article authored by (Avery Schwartz, Shany Blum, Rabea Asleh, Mordechai Pollak, Shiri Kalet-Litman, Andrew P Levy). Read article or submit your manuscript for publishing.Keywords
This publication has 58 references indexed in Scilit:
- Vitamin E Supplementation and Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.1999
- Oxidation of Low-Density Lipoprotein by Hemoglobin Stems from a Heme-Initiated Globin Radical: Antioxidant Role of HaptoglobinBiochemistry, 1997
- Biological and clinical significance of haptoglobin polymorphism in humansClinical Chemistry, 1996
- Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)The Lancet, 1996
- Identification of Proteins Associated with Apolipoprotein A-I-Containing Lipoproteins Purified by Selected-Affinity ImmunosorptionBiochemistry, 1994
- Beyond CholesterolNew England Journal of Medicine, 1989
- Structure and assembly of haptoglobin polymers by electron microscopyJournal of Molecular Biology, 1984
- High Density Lipoprotein Metabolism in ManJCI Insight, 1977
- THE FATE OF CIRCULATING HAEMOGLOBINBritish Journal of Haematology, 1975